Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer

Urology

Volumn 58, Issue 2 SUPPL. 1, 2001, Pages 39-48

  Gleave, Martin E ^a,b   Miyake, Hideaki ^a,b   Zellweger, Toby ^a,b   Chi, Kim ^a,b   July, Laura ^a,b   Nelson, Colleen ^a,b   Rennie, Paul ^a,b  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CALCIUM ANTAGONIST; CLUSTERIN; PACLITAXEL;

ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; CASTRATION; CELL SURVIVAL; CHEMOSENSITIVITY; CONFERENCE PAPER; CONTROLLED STUDY; DOSE RESPONSE; GENE EXPRESSION REGULATION; GENE TARGETING; HORMONE SENSITIVITY; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR BIOPSY; XENOGRAFT;

ANDROGEN ANTAGONISTS; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; APOPTOSIS; CALCIUM CHANNEL BLOCKERS; CELL DEATH; CLUSTERIN; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; GLYCOPROTEINS; HUMANS; MALE; MICE; MOLECULAR CHAPERONES; NEOADJUVANT THERAPY; OLIGONUCLEOTIDES, ANTISENSE; ORCHIECTOMY; PACLITAXEL; PROSTATIC NEOPLASMS; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0034909730     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(01)01241-9     Document Type: Conference Paper

References (69)

1. Overview of phase III trials on combined androgen treatment in patients with metastatic prostate cancer
2. Management of hormone refractory prostate cancer; current standards and future prospects
3. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer
4. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer
5. Phase II trial of oral estramustine, oral etopside, and intravenous paclitaxel in hormone-refractory prostate cancer
6. Genetic instability coupled to clonal selection as a mechanism for progression in prostatic cancer
7. Antisense Bcl-2 oligodeoxynucleotides delay progression to androgen-independence after castration in the androgen dependent Shionogi tumor model
8. Testosterone-repressed prostate message-2 (TRPM-2) is an antiapoptotic gene that confers resistance to androgen ablation in prostate cancer xenograft models
9. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma
10. Overexpression of insulin-like growth factor binding protein-5 helps accelerate progression to androgen-independence in the human prostate LNCaP tumor model through activation of phosphatidylinositol 3′-kinase pathway
11. Androgenic induction of prostate-specific antigen gene is repressed by protein-protein interaction between androgen receptor and AP-1c-Jun in the human prostate cancer cell line LNCaP
12. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase
13. Epidermal growth factor receptor activation in androgen-independent but not androgen-stimulated growth of human prostatic carcinoma cells
14. Mitogen-activated protein kinase 1 activates androgen receptor-dependent transcription and apoptosis in prostate cancer
15. The LNCaP cell line; a new model for studies on human prostatic carcinoma
16. Serum PSA levels in mice bearing human prostate LNCaP tumor are determined by tumor volume and endocrine and growth factors
17. Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft; LuCaP 23
18. Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1
19. Castration-induced apoptosis of androgen-dependent Shionogi carcinoma is associated with increased expression of genes encoding insulin-like growth factor binding proteins
20. Antisense Bcl-xL and Bcl-2 oligodeoxynucleotides synergistically enhance taxol chemosensitivity and delay progression to androgen-independence after castration in the androgen dependent Shionogi tumor model
21. Progression to androgen-independence is delayed by antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model
22. Hormone therapy failure in human prostate cancer; analysis by complementary DNA and tissue arrays
23. Immunohistochemical analysis of radical prostatectomy specimens after 8 months of neoadjuvant hormone therapy
24. Expression of the protooncogene Bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer
25. Detection of the apoptosis-suppressing oncoprotein Bcl-2 in hormone-refractory human prostate cancers
26. Overexpression of Bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo
27. Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice
28. Antisense Bcl-2 oligodeoxynucleotides enhance taxol chemosensitivity and synergistically delays progression to androgen-independence after castration in the androgen dependent Shionogi tumor model
29. Clusterin in the male reproductive tract
30. Apolipoprotein J (clusterin) and Alzheimer's disease
31. Clusterin and the kidney
32. Intracellular levels of SGP-2 (clusterin) correlate with tumor grade in prostate cancer
33. Direct transactivation of the anti-apoptotic gene apolipoprotein J (clusterin) by B-MYB
34. Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation
35. Overexpression of clusterin in human breast carcinoma
36. Detection of differentially expressed genes in lymphomas using cDNA arrays; identification of clusterin as a new diagnostic marker for anaplastic large-cell lymphomas
37. Gp80 (clusterin; TRPM-2) mRNA level is enhanced in human renal clear cell carcinomas
38. Androgen-repressed messages in the rat ventral prostate
39. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation
40. Active cell death in hormone-dependent tissues
41. Human gliomas and epileptic foci express high levels of a mRNA related to rat testicular sulfated glycoprotein 2, a purported marker of cell death
42. SGP-2 expression as a genetic marker of progressive cellular pathology in experimental hydronephrosis
43. Lack of association between enhanced TRPM-2/clusterin expression and increased apoptotic activity in sex-hormone-induced prostatic dysplasia of the Noble rat
44. Clusterin protects against oxidative stress in vitro through aggregative and nonaggregative properties
45. Distinct sites of production and deposition of the putative cell death marker clusterin in the human thymus
46. Nuclear clusterin/XIP8, an x-ray-induced Ku70-binding protein that signals cell death
47. Clusterin; a role in cell survival in the face of apoptosis
48. Clusterin is a secreted mammalian chaperone
49. Clusterin has chaperone-like activity similar to that of small heat shock proteins
50. Stress-induced transcription of the clusterin/apoJ gene
51. Cytotoxic sensitivity to tumor necrosis factor-α in PC3 and LNCaP prostatic cancer cells is regulated by extracellular levels of SGP-2 (Clusterin)
52. Bcl-x, a Bcl-2-related gene that functions as a dominant regulator of apoptotic cell death
53. Presence of the long and the short forms of Bcl-X in several human and murine tissues
54. Bcl-x(S) anatagonizes the protective effects of Bcl-x(L)
55. Genomic organization and expression of the rat TRPM-2 (clusterin) gene, a gene implicated in apoptosis
56. Clusterin biogenesis is altered during apoptosis in the regressing rat ventral prostate
57. Identification of glycoprotein 330 as an endocytic receptor for apolipoprotein J/clusterin
58. Prevention of cell death induced by tumor necrosis factor α in LNCaP cells by overexpression of sulfated glycoprotein-2 (clusterin)
59. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene, testosterone-repressed prostate message-2 (TRPM-2), in prostate cancer xenograft models
60. Therapeutic applications of oligonucleotides
61. Pharmacokinetics, tissue distribution, and stability of antisense oligodeoxynucleotide phosphorothioate ISIS 3466 in mice
62. Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase
63. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo
64. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence
65. Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-a expression
66. Chemosensitization of a human renal cell cancer model by antisense clusterin oligodeoxynucleotides both in vitro and in vivo
67. Bcl-2 overexpression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cells